Which drug is a second-generation antiepileptic that does not require therapeutic drug monitoring?

Which drug is a second-generation antiepileptic that does not require therapeutic drug monitoring?

• A. Gabapentin
• B. Phenytoin
• C. Valproic acid
• D. Ethosuximide

Answer: (A)

Therapeutic drug monitoring is most helpful for medicines with narrow safety margins or unpredictable behavior in the body. Among these antiepileptic drugs, gabapentin fits the pattern of not needing routine level checks because it is not significantly metabolized by the liver, has minimal drug interactions, and its dosing is guided largely by clinical response and renal function rather than measured serum concentrations. In practice, there isn’t a well-defined target plasma level to hit for gabapentin, so monitoring levels adds little value. Other older antiepileptics commonly require monitoring due to complex kinetics or toxicity risks: phenytoin has nonlinear, dose-dependent metabolism and a narrow therapeutic range, making levels important to avoid toxicity or inadequate seizure control; valproic acid has potential hepatotoxicity and other adverse effects that are monitored with labs and sometimes serum levels; ethosuximide can also require monitoring in certain clinical situations, though not as routinely as phenytoin or valproate. Thus, gabapentin is the best choice as a second-generation antiepileptic that does not require routine therapeutic drug monitoring.

Therapeutic drug monitoring is most helpful for medicines with narrow safety margins or unpredictable behavior in the body. Among these antiepileptic drugs, gabapentin fits the pattern of not needing routine level checks because it is not significantly metabolized by the liver, has minimal drug interactions, and its dosing is guided largely by clinical response and renal function rather than measured serum concentrations. In practice, there isn’t a well-defined target plasma level to hit for gabapentin, so monitoring levels adds little value. Other older antiepileptics commonly require monitoring due to complex kinetics or toxicity risks: phenytoin has nonlinear, dose-dependent metabolism and a narrow therapeutic range, making levels important to avoid toxicity or inadequate seizure control; valproic acid has potential hepatotoxicity and other adverse effects that are monitored with labs and sometimes serum levels; ethosuximide can also require monitoring in certain clinical situations, though not as routinely as phenytoin or valproate. Thus, gabapentin is the best choice as a second-generation antiepileptic that does not require routine therapeutic drug monitoring.